title: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
abstract: OBJECTIVE
  To compare prospectively the antitumor activity of single-agent paclitaxel to the three-drug combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer.
  
  
  METHODS
  Patients with T1-3N0-1M0 disease were randomized to receive either paclitaxel (250 mg/m(2)) as 24-hour infusion or FAC in standard doses at every-3-week intervals. Each patient was treated with four cycles of preoperative chemotherapy. Clinical response and extent of residual disease in the breast and lymph nodes was assessed after four cycles of induction chemotherapy.
  
  
  RESULTS
  A total of 174 patients were registered, and 87 were randomized to each arm of the study. Clinical response, ie, complete and partial responses, was similar in both arms of the study. Three patients in the FAC arm and one patient in the paclitaxel subgroup had progressive disease. The extent of residual disease by intent-to-treat analysis at the time of surgery was similar between the two arms of the study.
  
  
  CONCLUSIONS
  The results of this prospective study demonstrated that single-agent paclitaxel as neoadjuvant therapy has significant antitumor activity, and this was clinically comparable to FAC. Similar fractions of patients had clinical complete and partial responses, and very few patients had no response to either therapy. The value of alternate non-cross-resistant therapies as used in this protocol on the clinical course of this disease would require longer follow-up.
authors.affiliation: University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. abuzdar@mdanderson.org
authors.forename: A U
authors.initials: AU
authors.lastname: Buzdar
authors.forename: S E
authors.initials: SE
authors.lastname: Singletary
authors.forename: R L
authors.initials: RL
authors.lastname: Theriault
authors.forename: D J
authors.initials: DJ
authors.lastname: Booser
authors.forename: V
authors.initials: V
authors.lastname: Valero
authors.forename: N
authors.initials: N
authors.lastname: Ibrahim
authors.forename: T L
authors.initials: TL
authors.lastname: Smith
authors.forename: L
authors.initials: L
authors.lastname: Asmar
authors.forename: D
authors.initials: D
authors.lastname: Frye
authors.forename: N
authors.initials: N
authors.lastname: Manuel
authors.forename: S W
authors.initials: SW
authors.lastname: Kau
authors.forename: M
authors.initials: M
authors.lastname: McNeese
authors.forename: E
authors.initials: E
authors.lastname: Strom
authors.forename: K
authors.initials: K
authors.lastname: Hunt
authors.forename: F
authors.initials: F
authors.lastname: Ames
authors.forename: G N
authors.initials: GN
authors.lastname: Hortobagyi
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil